STOCK TITAN

BioCardia (BCDA) Financials

BCDA NASDAQ
FY2025 annual
Revenue $0 -100.0% YoY
Net Income -$8.2M n/m YoY
Free Cash Flow -$7.4M n/m YoY
Operating Cash Flow -$7.4M n/m YoY
Market Cap $11.9M as of Nov 20, 2026
Price / Sales n/m revenue is not positive, FY2025
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book 14.2x on $835K equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BCDA SEC filings page.

BioCardia, Inc. (BCDA) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI BCDA FY2025

BioCardia operates as a development-stage business: research spending and financing, not customer revenue, currently determine its financial profile.

FY2025’s net loss of $8.228M was closely matched by operating cash flow of -$7.436M, while capital expenditures were only $7K. That alignment means reported losses largely represent ongoing cash consumption rather than accounting charges being the main driver of the deficit.

The cost structure remains research-led. FY2024 revenue was only $58K against research and development spending of $4.387M; that spending then increased 13.1% to $4.962M in FY2025, even though FY2025 revenue is unavailable.

The balance sheet is being supported by financing inflows rather than operations: FY2025 financing cash flow was $7.568M versus operating cash flow of -$7.436M. Although equity recovered to $895K, liabilities still represented 73.8% of assets and the current ratio was 1.1x, leaving limited balance-sheet cushion relative to its funding needs.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for BioCardia, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Altman Z-Score Distress
-74.12

BioCardia, Inc. scores -74.12, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $168.3M against total assets of $3.4M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial
1/7

BioCardia, Inc. passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.

Earnings Quality No Cash Backing
N/A

BioCardia, Inc. reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA
-$1.8M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

BioCardia, Inc.'s EBITDA was -$1.8M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$1.8M
YoYn/m
QoQn/m
5Y CAGRn/m
10Y CAGRn/m

BioCardia, Inc. reported a net loss of $1.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Revenue

Not reported for Q3 2026.

EPS (Diluted)

Not reported for Q3 2026.

Cash & Balance Sheet

Free Cash Flow
-$1.7M
YoYn/m
QoQn/m
5Y CAGRn/m

BioCardia, Inc. recorded an outflow of $1.7M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$2.2M
YoY-57.9%
QoQ-46.0%
5Y CAGR-32.5%
10Y CAGR+15.0%

BioCardia, Inc. held $2.2M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
15M
YoY+42.6%
QoQ0.0%

BioCardia, Inc. had 15M shares outstanding in Q3 2026. This represents an increase of 42.6% from the same quarter a year earlier. It is unchanged from the prior quarter.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Return on Equity
-217.6%
YoY-161.2pp
QoQ-157.9pp

BioCardia, Inc.'s quarterly ROE was -217.6% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 161.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 157.9 percentage points.

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not reported for Q3 2026.

Net Margin

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1.2M
YoY+31.9%
QoQ+38.3%
5Y CAGR-11.2%
10Y CAGR+6.1%

BioCardia, Inc. invested $1.2M in research and development in Q3 2026. This represents an increase of 31.9% from the same quarter a year earlier. Against the prior quarter it is up 38.3%.

Capital Expenditures
$1K
YoYn/m
QoQn/m
5Y CAGR-45.1%

BioCardia, Inc. invested $1K in capex in Q3 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Share Buybacks

Not reported for Q3 2026.

BCDA Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-QQ4'2410-K
RevenueN/AN/AN/A$0n/m$0n/m$0-100.0%$0-100.0%$0-100.0%
R&D Expenses$1.2M+31.9%$893K-34.7%$1.2M-19.3%$1.1M-20.3%$936K+0.5%$1.4M+71.0%$1.5M+23.3%$1.4M+22.4%
SG&A ExpensesN/A$730K+6.9%$1.0M-13.8%$885K-2.3%$552K-33.1%$683K-19.8%$1.2M+9.8%$906K-3.7%
Operating Income-$1.8Mn/m-$1.6Mn/m-$2.3Mn/m-$2.0Mn/m-$1.5Mn/m-$2.1Mn/m-$2.7Mn/m-$2.3Mn/m
EBITDA-$1.8Mn/m-$1.6Mn/m-$2.3Mn/m-$2.0Mn/m-$1.5Mn/m-$2.0Mn/m-$2.7Mn/m-$2.3Mn/m
Income Tax$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Net Income-$1.8Mn/m-$1.6Mn/m-$2.3Mn/m-$2.0Mn/m-$1.5Mn/m-$2.0Mn/m-$2.7Mn/m-$2.3Mn/m
EPS (Basic)-$0.12n/m-$0.13-$0.21-$0.06-$0.24-$0.40-$0.59-$0.25
EPS (Diluted)N/AN/A-$0.21N/A-$0.24-$0.40-$0.59N/A
Diluted Shares (Avg)N/AN/A11MN/A6M5M5MN/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

BCDA Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-QQ4'2410-K
Total Assets$3.1M-50.0%$4.8M+127.6%$1.7M-21.0%$3.4M-8.4%$6.1M-1.9%$2.1M-27.7%$2.2M-19.1%$3.7M+24.7%
Current Assets$2.3M-56.5%$4.3M+258.5%$1.1M-2.8%$2.7M+4.2%$5.4M+6.1%$1.2M-23.8%$1.2M-6.8%$2.6M+79.5%
Cash & Equivalents$2.2M-57.9%$4.1M+320.1%$951K+0.2%$2.5M+5.3%$5.3M+7.2%$980K-31.0%$949K0.0%$2.4M+115.0%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Accounts Receivable$30K$30K+200.0%$20K$20Kn/mN/A$10K0.0%N/A$0-100.0%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$2.2M-36.5%$2.1M-48.3%$2.8M-24.6%$2.5M-12.8%$3.5M+0.2%$4.0M-18.1%$3.7M-25.6%$2.9M-37.1%
Current Liabilities$2.1M-36.8%$2.1M-43.6%$2.8M-14.1%$2.4M+4.8%$3.3M+16.5%$3.6M-10.5%$3.2M-20.6%$2.3M-35.7%
Non-Current Liabilities$144K-31.8%$0-100.0%$0-100.0%$86K-84.8%$211K-68.7%$333K-57.3%$452K-48.8%$566K-42.4%
Total Equity$835K-68.2%$2.7Mn/m-$1.1Mn/m$895K+6.9%$2.6M-4.6%-$1.9Mn/m-$1.5Mn/m$837Kn/m
Retained Earnings-$174.0Mn/m-$172.2Mn/m-$170.6Mn/m-$168.3Mn/m-$166.4Mn/m-$164.9Mn/m-$162.8Mn/m-$160.1Mn/m

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

BCDA Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-QQ4'2410-K
Operating Cash Flow-$1.7Mn/m-$1.7Mn/m-$1.7Mn/m-$2.5Mn/m-$1.7Mn/m-$1.6Mn/m-$1.6Mn/m-$2.4Mn/m
Depreciation & Amortization$2K-50.0%$3K-40.0%$3K-75.0%$3K-80.0%$4K-75.0%$5K-70.6%$12K-36.8%$15K-25.0%
Stock-Based Compensation$117K+51.9%$109K+11.2%$113K-33.5%N/A$77K-56.5%$98K-46.7%$170K-16.7%N/A
Capital Expenditures$1Kn/m$0-100.0%$3Kn/m$6K+500.0%$0-100.0%$1K-66.7%$0n/m$1Kn/m
Free Cash Flow-$1.7Mn/m-$1.7Mn/m-$1.7Mn/m-$2.5Mn/m-$1.7Mn/m-$1.6Mn/m-$1.6Mn/m-$2.4Mn/m
Investing Cash Flow-$1Kn/m$0n/m-$3Kn/m-$6Kn/m$0n/m-$1Kn/m$0n/m-$1Kn/m
Financing Cash Flow-$172K-102.9%$4.9M+191.6%$117K-40.3%-$288Kn/m$6.0M-2.3%$1.7M-5.9%$196K-85.8%-$125K-111.2%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

BCDA Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

BCDA quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-Q/AQ1'2510-QQ4'2410-K
Return on Equity-217.6%-161.2pp-59.7%N/A-221.7%+52.6pp-56.5%+6.6ppN/AN/A-274.3%
Return on Assets-59.2%-35.1pp-33.9%+64.2pp-131.9%-6.7pp-58.1%+3.5pp-24.1%+3.6pp-98.1%-41.1pp-125.2%-40.6pp-61.7%+7.7pp
Current Ratio1.11-0.5x2.09+1.8x0.410.0x1.120.0x1.62-0.2x0.33-0.1x0.36+0.1x1.13+0.7x
Liabilities-to-Equity2.68+1.3x0.76N/A2.81-0.6x1.34+0.1xN/AN/A3.45
Asset TurnoverN/AN/AN/A0.000.0x0.000.0x0.000.0x0.000.0x0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, FCF Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
BioCardia, Inc. BCDA FY2025 $0 -$8.2M N/A $11.9M —
Psyence Biomedical Ltd. PBM FY2026 N/A -$6.9M N/A $11.3M —
Fractyl Health, Inc. GUTS FY2025 $0 -$141.0M N/A $10.9M —
Citius Pharmaceuticals Inc. CTXR FY2025 N/A -$37.4M N/A $14.0M —
Bolt Biotherapeutics, Inc. BOLT FY2025 $7.7M -$33.4M N/A $12.8M 58/100
Seres Therapeutics, Inc. MCRB FY2025 $789K $5.7M N/A $12.6M —

Frequently Asked Questions

BioCardia, Inc. (BCDA) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

BioCardia, Inc. (BCDA) revenue declined by 100.0% year-over-year, from $58K to $0 in fiscal year 2025.

No, BioCardia, Inc. (BCDA) reported a net loss of $8.2M in fiscal year 2025.

BioCardia, Inc. (BCDA) had EBITDA of -$8.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

BioCardia, Inc. (BCDA) has a return on equity of -919.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

BioCardia, Inc. (BCDA) recorded an outflow of $7.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

BioCardia, Inc. (BCDA) recorded an outflow of $7.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

BioCardia, Inc. (BCDA) had $3.4M in total assets as of fiscal year 2025, including both current and long-term assets.

BioCardia, Inc. (BCDA) invested $7K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

BioCardia, Inc. (BCDA) invested $5.0M in research and development during fiscal year 2025.

BioCardia, Inc. (BCDA) had 11M shares outstanding as of fiscal year 2025.

BioCardia, Inc. (BCDA) had a current ratio of 1.12 as of fiscal year 2025, which is considered adequate.

BioCardia, Inc. (BCDA) had a liabilities-to-equity ratio of 2.81 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.

BioCardia, Inc. (BCDA) had a return on assets of -241.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

BioCardia, Inc. (BCDA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $11.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

BioCardia, Inc. (BCDA) has no price-to-sales ratio at the moment: revenue is not positive (FY2025). The market capitalization is $11.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, BioCardia, Inc. (BCDA) held $2.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $7.4M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

BioCardia, Inc. (BCDA) has an Altman Z-Score of -74.12, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

BioCardia, Inc. (BCDA) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

BioCardia, Inc. (BCDA) reported a net loss of $8.2M while operations used $7.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Back to top